Loading organizations...
§ Private Profile · Nanjing, Jiangsu, China
Clinical-stage biopharmaceutical company developing liver disease therapies, including NASH and hepatitis B.
Hepagene Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative small molecule therapies for a range of severe liver diseases, including nonalcoholic steatohepatitis (NASH), liver cirrhosis, and hepatitis B. Its pipeline features HPG-1860, an FXR agonist, which recently completed its Phase 2a RISE study, achieving its clinical endpoint with data presented at EASL 2023 and published in the Journal of Medicinal Chemistry in 2023. Another key candidate, HPG-7233, a THR-β agonist, is progressing towards initiating its Phase 1 clinical trials in the latter half of a recent year. Operating as a venture-backed clinical-stage biotech, the company has secured investments from firms such as Morningside and Apricot, and is led by President and CEO Dr. Xu. Hepagene Therapeutics was founded in 2016.
Hepagene Therapeutics has raised $40.0M across 1 funding round.
Hepagene Therapeutics has raised $40.0M in total across 1 funding round.
Hepagene Therapeutics has raised $40.0M across 1 funding round. Most recently, it raised $40.0M Series B in April 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 26, 2021 | $40M Series B | Loyal Valley Capital | Apricot Capital, Oceanpine Capital | Announced |
Hepagene Therapeutics has raised $40.0M in total across 1 funding round.
Hepagene Therapeutics's investors include Loyal Valley Capital, Apricot Capital, Oceanpine Capital.